A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
Trial status:Study Complete
Trial ID:
C4591017
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete
Trial Details
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): * As a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches) * As a 20-microgram dose, administered from 1 of the manufacturing lots * As a 2-dose (separated by 21 days) schedule * In people 12 through 50 years of age The booster study will evaluate the safety, tolerability, and immunogenicity of 2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351): * Each as a 30-microgram dose * Each as a 1-dose booster vaccine, administered approximately 3 months after Dose 2 * In people 18 through 50 years of age
Medical Condition
Trial Drug
See more
Phase
Phase 3
Type
Interventional
Estimated Enrolment
1574
Estimated Trial Date
Feb 2021 - Jul 2021
Trial Participant Requirements
Age
12 - 50 Years
Sex
Female & Male
Healthy Volunteers
Yes
Trial Locations
Location
Status
Location
Kaiser Permanente Oakland
Oakland, California, United States, 94611
Status
Location
Clinical Research Consulting
Milford, Connecticut, United States, 06460
Status
Location
Indago Research & Health Center, Inc
Hialeah, Florida, United States, 33012
Status
Location
Research Centers of America
Hollywood, Florida, United States, 33024
Status
Location
Clinical Neuroscience Solutions
Orlando, Florida, United States, 32801
Status
Location
Clinical Research Atlanta
Stockbridge, Georgia, United States, 30281
Status